Wells Fargo’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.32M | Buy |
82,506
+49,298
| +148% | +$3.6M | ﹤0.01% | 2480 |
|
|
2026
Q1 | $1.68M | Sell |
33,208
-49,208
| -60% | -$1.86M | ﹤0.01% | 3398 |
|
|
2025
Q4 | $2.7M | Buy |
82,416
+43,097
| +110% | +$1.13M | ﹤0.01% | 3197 |
|
|
2025
Q3 | $659K | Buy |
39,319
+4,910
| +14% | +$80.1K | ﹤0.01% | 4101 |
|
|
2025
Q2 | $515K | Buy |
34,409
+4,374
| +15% | +$64.7K | ﹤0.01% | 4126 |
|
|
2025
Q1 | $485K | Buy |
30,035
+5,317
| +22% | +$111K | ﹤0.01% | 4118 |
|
|
2024
Q4 | $575K | Buy |
24,718
+6,908
| +39% | +$203K | ﹤0.01% | 4077 |
|
|
2024
Q3 | $524K | Buy |
17,810
+635
| +4% | +$17.7K | ﹤0.01% | 3964 |
|
|
2024
Q2 | $404K | Buy |
17,175
+14,933
| +666% | +$504K | ﹤0.01% | 4048 |
|
|
2024
Q1 | $85K | Buy |
2,242
+2,219
| +9,648% | +$64.3K | ﹤0.01% | 4981 |
|
|
2023
Q4 | $495 | Buy |
23
+1
| +5% | +$14 | ﹤0.01% | 6384 |
|
|
2023
Q3 | $270 | Sell |
22
-328
| -94% | -$4.33K | ﹤0.01% | 6511 |
|
|
2023
Q2 | $3.94K | Buy |
350
+21
| +6% | +$100 | ﹤0.01% | 6111 |
|
|
2023
Q1 | $2.38K | Buy |
329
+227
| +223% | +$2.49K | ﹤0.01% | 6199 |
|
|
2022
Q4 | $1.15K | Buy |
102
+1
| +1% | +$18 | ﹤0.01% | 6142 |
|
|
2022
Q3 | $1K | Buy |
101
+3
| +3% | +$37 | ﹤0.01% | 6468 |
|
|
2022
Q2 | $1K | Sell |
98
-183
| -65% | -$6.41K | ﹤0.01% | 6606 |
|
|
2022
Q1 | $16K | Sell |
281
-572
| -67% | -$48K | ﹤0.01% | 6106 |
|
|
2021
Q4 | $101K | Buy |
853
+765
| +869% | +$121K | ﹤0.01% | 5635 |
|
|
2021
Q3 | $18K | Hold |
88
| – | – | ﹤0.01% | 6009 |
|
|
2021
Q2 | $16K | Sell |
88
-385
| -81% | -$70K | ﹤0.01% | 5988 |
|
|
2021
Q1 | $94K | Sell |
473
-1,049
| -69% | -$201K | ﹤0.01% | 5517 |
|
|
2020
Q4 | $300K | Buy |
1,522
+217
| +17% | +$45K | ﹤0.01% | 4878 |
|
|
2020
Q3 | $232K | Sell |
1,305
-50
| -4% | -$9.25K | ﹤0.01% | 4888 |
|
|
2020
Q2 | $313K | Sell |
1,355
-1,385
| -51% | -$264K | ﹤0.01% | 4649 |
|
|
2020
Q1 | $319K | Buy |
2,740
+511
| +23% | +$86.9K | ﹤0.01% | 4374 |
|
|
2019
Q4 | $425K | Sell |
2,229
-3
| -0.1% | -$589 | ﹤0.01% | 4497 |
|
|
2019
Q3 | $429K | Sell |
2,232
-217
| -9% | -$42.3K | ﹤0.01% | 4479 |
|
|
2019
Q2 | $419K | Buy |
2,449
+830
| +51% | +$143K | ﹤0.01% | 4504 |
|
|
2019
Q1 | $326K | Buy |
1,619
+56
| +4% | +$11.7K | ﹤0.01% | 4580 |
|
|
2018
Q4 | $293K | Buy |
1,563
+819
| +110% | +$174K | ﹤0.01% | 4686 |
|
|
2018
Q3 | $178K | Sell |
744
-1,344
| -64% | -$314K | ﹤0.01% | 5063 |
|
|
2018
Q2 | $552K | Buy |
2,088
+997
| +91% | +$245K | ﹤0.01% | 4371 |
|
|
2018
Q1 | $271K | Buy |
1,091
+174
| +19% | +$31.4K | ﹤0.01% | 4809 |
|
|
2017
Q4 | $124K | Buy |
917
+176
| +24% | +$21.5K | ﹤0.01% | 5216 |
|
|
2017
Q3 | $91K | Sell |
741
-145
| -16% | -$13.6K | ﹤0.01% | 5265 |
|
|
2017
Q2 | $85K | Buy |
886
+258
| +41% | +$35.7K | ﹤0.01% | 5230 |
|
|
2017
Q1 | $117K | Sell |
628
-63
| -9% | -$8.89K | ﹤0.01% | 5131 |
|
|
2016
Q4 | $75K | Buy |
691
+579
| +517% | +$84.4K | ﹤0.01% | 5269 |
|
|
2016
Q3 | $18K | Buy |
112
+20
| +22% | +$2.78K | ﹤0.01% | 5621 |
|
|
2016
Q2 | $11K | Buy |
+92
| New | +$17.6K | ﹤0.01% | 5643 |
|
Other funds holding SYRE
PA
RI
PBA
VA
DCM
Wells Fargo's SYRE Position: Q2 2026 in Review
Wells Fargo increased its Spyre Therapeutics (SYRE) stake by 148% in Q2 2026, buying an estimated $3.6M and bringing the position to 82,506 shares worth $7.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2480.
Wells Fargo first reported a position in SYRE in Q2 2016 and has held it in 41 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.
- Wells Fargo held 82,506 shares of Spyre Therapeutics worth $7.32M as of Q2 2026.
- Wells Fargo bought 49,298 Spyre Therapeutics shares in Q2 2026, an estimated $3.6M.
- Spyre Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #2480 holding.
- Wells Fargo first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 41 quarters since.
- 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.